Bringing new technologies to life

Spark Sigma are experts in technology commercialization. From the lab to the marketplace.

About us
SparkSigma™ is developing SyncroScan™, the only handheld portable diagnostic and therapeutic device that can identify and destroy any pathogen (bacteria/viruses/fungi) instantaneously on any surface. The company will focus initially upon wound care and surgery applications.


The Problem in Wound Care

There is an existing $5B need to precisely detect and classify the pathogen in a wound so that the most
effective antibiotic may be employed, progress of the wound’s healing may be accurately tracked and the
effectiveness of topical antimicrobial treatments may be confirmed.

The Problem in Surgical Infection

~700,000 surgical patients develop Hospital Associated Infections (HAI) annually in US hospitals.
Treating these lesions represents a $0.5B opportunity for SparkSigma. Preventing these lesions
intraoperatively is a much larger opportunity, but it is not addressed in the Company’s current plan.

The Solution for Wounds 

Hand-held SyncroScan™ illuminates the wound with an array of different wavelengths of light, causing any
pathogen present to emit a precise fluorescence signal that instantaneously measures the concentration of every pathogen in the wound. SyncroScan™’s CCD camera measures the wound’s length, width and depth, then automatically feeds that data into the patient’s EMR (Electronic Medical Record). Gen 2 will be equipped with a UVC-emitting capability to destroy all pathogens in the device’s field of view. Top wound clinicians love SyncroScan™ because it improves patient outcomes and lowers costs (caregiver time).

The Solution for Surgery

SyncroScan™ will scan the surgical site before, during and after a surgical procedure to ensure that no
infection is present at any stage of the procedure. If post-op infection is detected, the pathogen will be
identified, helping both in treatment and in locating the source of the infection in the hospital. Gen 2 will
destroy all pathogens in the device’s field of view.


SyncroScan™ is basically an emission spectrometer that utilizes proprietary synchronous UV- Vis scanning, excitation-emission/fluorescence and Principle Component Analysis (PCA) software. SyncroScan™ is able to instantaneously identify multiple pathogenic types in unknown samples by matching them with the company’s spectroscopic “fingerprint” library. SyncroScan’s proprietary software incorporates Machine Learning and AI to expand speed, accuracy and security of data acquisition, analysis and storage.

The Company is raising capital to complete the development of its SyncroScan™ system, and launch it in the marketplace. If you are interested in investing in, or, partnering with SparkSigma please contact us. 

Invest or Partner with us

Leadership Team

Dennis G. Lockyer

(President and Founder) has more than 40 years of industrial management experience. As President of Crane Technical Materials, he grew a start-up business to a globally recognized company, that sold to Neenah (NYSE:NP).  Dennis held BOD Positions for companies in Asia and Europe and serves on Texas A&M’s College of Science External Advisory and Development Committee.


Co-inventor on six (6) patent families with applications and patents totaling 43. Holds a B.S. Chemistry, Texas A&M University (1977) and a M.S. Industrial Administration, Union College (1993). 

Russell A. Hoon

(Vice President and Co-Founder) brings to SparkSigma more than 35 years of experience in medical product development, operational scale up, clinical trials, sales, marketing, and management at all levels.


Over the course of his career, Mr. Hoon’s expertise has been critical in the clinical development, regulatory approval process, manufacturing scale-up, and sales and marketing of various medical products and devices. To date, Mr. Hoon has brought over twenty medical devices to market. Mr. Hoon also holds a process patent as well as several patent applications. Mr. Hoon is the co-author of several clinical and scientific publications. 

Greg Zaic

(Interim CFO) Greg brings over 25 years of private equity  investment and business development experience,  primarily in medtech and pharma. He has served on more than 20 boards of directors both private and publicly traded companies and has been involved  with 7 IPOs and 5 mergers.


He holds a B.S. Engineering, Princeton University and a M.S. Engineering and M.S. Management, Massachusetts Institute of Technology. Greg currently sits on the Columbia University Department of Ophthalmology Board of Advisors.

Contact Us



+1 413 822 1796

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from Youtube
Consent to display content from Vimeo
Google Maps
Consent to display content from Google
Consent to display content from Spotify
Sound Cloud
Consent to display content from Sound